RXi Pharmaceuticals of Worcester is expanding the patent protection of its newly acquired drug.
RXi received additional patents to cover the worldwide rights to use NeuVax, a breast cancer therapy drug that was developed by Apthera. RXi purchased Apthera in April.
The company recently reported positive results from its phase-II clinical trial of NeuVax and expects to undertake a phase III clinical trial next year.
The patents were licensed from the Henry M. Jackson Foundation for the Advancement of Military Medicine Inc.
